ArticleMolecular diversity2026
Synthesis of imidazo[2,1-a]isoquinolin-5-ones via C-H imidoylmethylation/oxidation/cyclization cascade of 2-arylbenzimidazoles with CF
Article in Molecular diversity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Recent progress in the application of CFMolecular diversity · 2026Review
- A magnetically recoverable MOF-derived nanocatalyst for the efficient synthesis of organic heterocycles with pharmaceutical and agricultural properties.Molecular diversity · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
A direct C-H imidoylmethylation and subsequent oxidation/cyclization reaction of 2-arylbenzimidazoles with CF
Indexed as
Identifiers
41417191What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.